Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Perennial Allergic Rhinitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Perennial Allergic Rhinitis - Pipeline Review, H1 2016', provides an overview of the Perennial Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis - The report reviews pipeline therapeutics for Perennial Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Perennial Allergic Rhinitis therapeutics and enlists all their major and minor projects - The report assesses Perennial Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Perennial Allergic Rhinitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Perennial Allergic Rhinitis Overview 8 Therapeutics Development 9 Pipeline Products for Perennial Allergic Rhinitis - Overview 9 Pipeline Products for Perennial Allergic Rhinitis - Comparative Analysis 10 Perennial Allergic Rhinitis - Therapeutics under Development by Companies 11 Perennial Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 12 Perennial Allergic Rhinitis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Perennial Allergic Rhinitis - Products under Development by Companies 15 Perennial Allergic Rhinitis - Products under Investigation by Universities/Institutes 16 Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development 17 Adamis Pharmaceuticals Corporation 17 Chong Kun Dang Pharmaceutical Corp. 18 Faes Farma, SA 19 GenMont Biotech Inc. 20 Hanmi Pharmaceuticals, Co. Ltd. 21 Hisamitsu Pharmaceutical Co., Inc. 22 Merck & Co., Inc. 23 Pfizer Inc. 24 Shionogi & Co., Ltd. 25 VentiRx Pharmaceuticals, Inc. 26 Perennial Allergic Rhinitis - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 (levocabastine hydrochloride + mometasone furoate) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 (levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 APC-3000 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 asapiprant - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 bilastine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 desloratadine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 emedastine difumarate - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 GMNL-32 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 PF-06444752 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 PF-06444753 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 VTX-1463 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Perennial Allergic Rhinitis - Recent Pipeline Updates 52 Perennial Allergic Rhinitis - Dormant Projects 55 Perennial Allergic Rhinitis - Discontinued Products 56 Perennial Allergic Rhinitis - Product Development Milestones 57 Featured News & Press Releases 57 Aug 13, 2015: PENDOPHARM announces Nasacort Allergy 24H Nasal Spray is now available without a prescription in Canadian Province 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Perennial Allergic Rhinitis, H1 2016 9 Number of Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Perennial Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016 17 Perennial Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 18 Perennial Allergic Rhinitis - Pipeline by Faes Farma, SA, H1 2016 19 Perennial Allergic Rhinitis - Pipeline by GenMont Biotech Inc., H1 2016 20 Perennial Allergic Rhinitis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 21 Perennial Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 22 Perennial Allergic Rhinitis - Pipeline by Merck & Co., Inc., H1 2016 23 Perennial Allergic Rhinitis - Pipeline by Pfizer Inc., H1 2016 24 Perennial Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H1 2016 25 Perennial Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016 26 Assessment by Monotherapy Products, H1 2016 27 Assessment by Combination Products, H1 2016 28 Number of Products by Stage and Target, H1 2016 30 Number of Products by Stage and Mechanism of Action, H1 2016 32 Number of Products by Stage and Route of Administration, H1 2016 34 Number of Products by Stage and Molecule Type, H1 2016 36 Perennial Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H1 2016 52 Perennial Allergic Rhinitis - Dormant Projects, H1 2016 55 Perennial Allergic Rhinitis - Discontinued Products, H1 2016 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
